Bausch + Lomb Corp at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm Robbie Marcus, the medtech analyst at JPMorgan. Very happy to have Bausch + Lomb as our next session. I'm going to introduce CEO, Joe Papa, for a presentation, and then, we're going to do a little bit of Q&A after. Joe?
+-&
Thank you, Robbie. It's a pleasure to be here and a pleasure to -- this is great to be here as Bausch + Lomb with the very first time presenting at the JPMorgan Conference in over a decade as a public company. So we're delighted to have the chance today to be here.
As a reminder, I'm going to go through a number of slides and I'll refer you to our SEC filings for any of the risk factors. It's a pleasure for me to have a chance to review Bausch + Lomb in terms of the investment thesis of Bausch + Lomb. As a company, we are a pure play eye health company. That's how we formed ourselves as we thought forward. We participate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |